Skip to content

'The effects of Omega-3 Fatty Acids Dietary Supplements (Fish Oil) on Impulsivity in Patients with a Personality Disorder'

'The effects of Omega-3 Fatty Acids Dietary Supplements (Fish Oil) on Impulsivity in Patients with a Personality Disorder' - Omega-3 Fatty Acids and Impulsivity

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON30834
Enrollment
70
Registered
2007-09-14
Start date
2007-06-25
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

impulsiviteit impulscontrol problem impulsivity

Interventions

Subjects are prescribed to take in fish oil - or placebo capsules (randomly assigned and double blind) for 8 weeks on a daily basis. Impulsivity (and other psychological symptoms) will be measured a

Sponsors

Universiteit Leiden
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Dutch speaking men and women - Presence of a cluster B personality disorder or a Personality disorder Not Otherwise Specified (according to the DSM-IV) - Presence of impulsivity (according to the DSM-IV diagnostic criteria for impulsivity in the Axis II Personality disorders and according to the Barratt Impulsiveness Scale BIS-11)

Exclusion criteria

Exclusion criteria: - Current substance abuse or dependence (DSM-IV criteria) - Current use of medication, unless the intake is stable - Current use of omega-3 fatty acids dietary supplements or eating more than 1 fatty fish per week - Diagnosis of a psychotic disorder, bipolar disorder or a major depressive episode (DSM-IV criteria) - Patients, participating in the module for Impulscontrol (CPP) during the 8 weeks of the study.

Design outcomes

Primary

MeasureTime frame
The primary study parameter is impulsivity, which will be measured by self-report questionnaires and computerized cognitive tasks.

Secondary

MeasureTime frame
The secondary study parameters are several psychological symptoms, among which depression. These complaints will be measured by a self-report questionnaire and a semi-standardized interview-observation scale.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)